About Neprilysin
Neprilysin (MME) is a protein
from Homo sapiens identified by UniProt accession
P08473, 750 residues long.
MolForge cross-references it against 0 known binders and
914 disease associations.
Target properties
| Protein name | Neprilysin |
|---|
| UniProt accession | P08473 |
|---|
| Gene | MME |
|---|
| Organism | Homo sapiens |
|---|
| Length | 750 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (4)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (914)
Diseases linked to this target (Open Targets).
- Charcot-Marie-Tooth disease axonal type 2T · score 0.75
- charcot-marie-tooth disease, axonal, type 2t · score 0.71
- spinocerebellar ataxia 43 · score 0.60
- heart failure · score 0.59
- Reduced left ventricular ejection fraction · score 0.54
- congestive heart failure · score 0.50
- systolic heart failure · score 0.46
- Spinocerebellar ataxia type 43 · score 0.46
- congenital membranous nephropathy due to maternal anti-neutral endopeptidase alloimmunization · score 0.45
- myocardial infarction · score 0.41
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P08473-F1 | alphafold | PREDICTED | 96.20 | — |
Amino-acid sequence (750 residues)
MGKSESQMDI TDINTPKPKK KQRWTPLEIS LSVLVLLLTI IAVTMIALYA TYDDGICKSS DCIKSAARLI QNMDATTEPC TDFFKYACGG WLKRNVIPET SSRYGNFDIL RDELEVVLKD VLQEPKTEDI VAVQKAKALY RSCINESAID SRGGEPLLKL LPDIYGWPVA TENWEQKYGA SWTAEKAIAQ LNSKYGKKVL INLFVGTDDK NSVNHVIHID QPRLGLPSRD YYECTGIYKE ACTAYVDFMI SVARLIRQEE RLPIDENQLA LEMNKVMELE KEIANATAKP EDRNDPMLLY NKMTLAQIQN NFSLEINGKP FSWLNFTNEI MSTVNISITN EEDVVVYAPE YLTKLKPILT KYSARDLQNL MSWRFIMDLV SSLSRTYKES RNAFRKALYG TTSETATWRR CANYVNGNME NAVGRLYVEA AFAGESKHVV EDLIAQIREV FIQTLDDLTW MDAETKKRAE EKALAIKERI GYPDDIVSND NKLNNEYLEL NYKEDEYFEN IIQNLKFSQS KQLKKLREKV DKDEWISGAA VVNAFYSSGR NQIVFPAGIL QPPFFSAQQS NSLNYGGIGM VIGHEITHGF DDNGRNFNKD GDLVDWWTQQ SASNFKEQSQ CMVYQYGNFS WDLAGGQHLN GINTLGENIA DNGGLGQAYR AYQNYIKKNG EEKLLPGLDL NHKQLFFLNF AQVWCGTYRP EYAVNSIKTD VHSPGNFRII GTLQNSAEFS EAFHCRKNSY MNPEKKCRVW
Explore Neprilysin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets